Indolent Primary Cutaneous T Cell Lymphoma C5680498
A slow-progressing skin cancer involving T cells. It often appears as scaly patches or plaques and is typically managed with topical treatments or light therapy.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Weight loss (systemic)
Generalized symptoms
(oncologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Skin patches (flat lesions)
(integumentary)Pruritus (itching)
(integumentary)Skin plaques with thickening
(integumentary)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Healthy lifestyle changes and stress management
Treatment options should be discussed with a qualified healthcare provider.
Topical Corticosteroid Therapy
High-potency topical corticosteroids applied directly to patches or plaques. First-line therapy for early-stage disease with good response rates and minimal systemic toxicity.
Phototherapy (PUVA/NB-UVB)
Controlled ultraviolet light exposure in clinical settings to suppress abnormal T-cell proliferation. Requires regular sessions and careful dosimetry to maximize benefit while minimizing skin cancer risk.
Additional treatment options
Topical Retinoid Therapy
Application of vitamin A-derived topical agents to promote normal skin cell differentiation and reduce abnormal cell accumulation in affected areas.
medicationSystemic Retinoid Therapy
Oral retinoid medications for more advanced or widespread disease. These agents normalize skin cell turnover and have immunomodulatory properties.
medicationStaged Disease Monitoring
Comprehensive staging workup followed by regular monitoring for disease progression. Includes regular skin examinations and periodic laboratory assessment.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Indolent Primary Cutaneous T Cell Lymphoma C5680498?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Willemze R, Pimpinelli N, Burg G, et al. EORTC/ISCL consensus recommendations for the treatment of primary cutaneous lymphomas. Blood. 2020.
Kempf W, Ostheeren-Michaelis S, Paulli M, et al. The role of skin-directed therapies in the management of indolent T-cell lymphoproliferative disorders. J Am Acad Dermatol. 2018.
Hristov AC, Tejasvi T, Wilcox RA, et al. Long-term outcomes of low-dose methotrexate in early-stage mycosis fungoides: a phase II clinical trial. J Clin Oncol. 2021.
Bagherani N, Smoller BR, Horn TD. Current concepts in the classification of cutaneous lymphomas. Dermatol Clin. 2019.
Medication Comparisons
Compare medications used to treat Indolent Primary Cutaneous T Cell Lymphoma C5680498. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy